HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence
Xiao Zhang, Liu Huang, Jiayao Li, Yixin Cai, Wei Chen, Yijiu Ren, Xianglin Yuan, Wei Sun, Shuguo Sun, Qian Chu · 2026
Read HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence by Xiao Zhang, Liu Huang, Jiayao Li, Yixin Cai, Wei Chen, Yijiu Ren, Xianglin Yuan, Wei Sun, Shuguo Sun, Qian Chu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289227.txt.
Description
Xiao Zhang and colleagues published a 2026 study on why some lung cancers resist immune therapy. They focus on YAP, a protein that helps tumors hide from the immune system, in non-small cell lung cancer. The team also tested whether drugs that block histone deacetylases, called HDAC inhibitors, can undo that resistance.
Records covered 141 patients who got immune therapy alone or with chemotherapy or blood vessel drugs. High YAP in tumor tissue linked to worse results, and YAP predicted response better than PD-L1 in this group. Lab work after lowering YAP and its partner TAZ pointed to candidate blockers. Two patients with high YAP who had stopped responding were also treated, giving early human support for the lab findings.
Catalog record
| CREATOR | Xiao Zhang, Liu Huang, Jiayao Li, Yixin Cai, Wei Chen, Yijiu Ren, Xianglin Yuan, Wei Sun, Shuguo Sun, Qian Chu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53295 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |